Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients
Eur J Cancer
.
2019 Jul:116:114-115.
doi: 10.1016/j.ejca.2019.05.017.
Epub 2019 Jun 10.
Authors
Taketo Kawai
1
,
Yusuke Sato
2
,
Katsuhiro Makino
2
,
Yuta Yamada
2
,
Akira Nomiya
2
,
Masaki Nakamura
2
,
Daisuke Yamada
2
,
Motofumi Suzuki
2
,
Yasuhiko Igawa
2
,
Haruki Kume
2
Affiliations
1
Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Electronic address: taketokawai@yahoo.co.jp.
2
Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
PMID:
31195355
DOI:
10.1016/j.ejca.2019.05.017
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Carcinoma, Transitional Cell*
Humans
Urologic Neoplasms*
Substances
Antibodies, Monoclonal, Humanized
pembrolizumab